Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...
AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ...
Researchers have developed a simple model system that can be used to break down fibrils -- the cause of numerous disorders including Alzheimer's and Parkinson's disease -- into their constituent ...
Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...
A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...
There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.
18, 2024 -- The FDA has approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev ... their symptoms with traditional medications or surgery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback